首页> 外文期刊>Vascular and endovascular surgery >Cool excimer laser-assisted angioplasty (CELA) and tibial balloon angioplasty (TBA) in management of infragenicular arterial occlusion in critical lower limb ischemia (CLI)
【24h】

Cool excimer laser-assisted angioplasty (CELA) and tibial balloon angioplasty (TBA) in management of infragenicular arterial occlusion in critical lower limb ischemia (CLI)

机译:冷准分子激光辅助血管成形术(CELA)和胫骨球囊血管成形术(TBA)在重症下肢缺血(CLI)中处理膝下肌动脉阻塞

获取原文
获取原文并翻译 | 示例
       

摘要

We aim to compare cool excimer laser-assisted angioplasty (CELA) versus tibial balloon angioplasty (TBA) in patients with critical limb ischemia (CLI) with tibial artery occlusive disease. The primary end point is sustained clinical improvement (SCI) and amputation-free survival (AFS). The secondary end points are binary restenosis, target extremity revascularization (TER), and cost-effectiveness. From June 2005 to October 2010, 1506 patients were referred with peripheral vascular disease and 572 with CLI. A total of 80 patients underwent 89 endovascular revascularizations (EVRs) for tibial occlusions, 47 using TBA and 42 using CELA. All patients were Rutherford category 4 to 6. Three-year SCI was enhanced with CELA (81%) compared to TBA (63.8%; P =.013). Three-year AFS significantly improved with CELA (95.2%) versus TBA (89.4%; P =.0165). Three-year freedom from TER was significantly improved with CELA (92.9%) versus 78.7% TBA (P =.026). Three-year freedom from MACE was comparable in both the groups (P =.455). Patients with CELA had significantly improved quality time without symptoms of disease or toxicity of treatment (Q-TWiST) at 3 years (10.5 months; P =.048) with incremental cost of ?2073.19 per quality-adjusted life year gained. Tibial EVR provides exceptional outcome in CLI. The CELA has superior SCI, AFS, and freedom from TER, with improved Q-TWiST and cost-effectiveness.
机译:我们的目的是比较重度肢体缺血(CLI)伴有胫骨动脉闭塞性疾病的患者的冷准分子激光辅助血管成形术(CELA)与胫骨球囊血管成形术(TBA)。主要终点是持续的临床改善(SCI)和无截肢生存(AFS)。次要终点是二元再狭窄,目标肢端血运重建(TER)和成本效益。从2005年6月到2010年10月,共转诊1506例周围血管疾病患者和572例CLI患者。共有80例患者进行了89次胫骨阻塞的血管内血运重建术(EVR),其中47例使用TBA,42例使用CELA。所有患者均为Rutherford 4至6类。CELA增强了三年SCI(81%),而TBA(63.8%; P = .013)。与TBA(89.4%; P = .0165)相比,CELA(95.2%)的三年AFS显着改善。 CELA(92.9%)显着改善了三年免于TER的机会,而TBA则为78.7%(P = .026)。在两组中,从MACE获得的三年自由度均相当(P = .455)。 CELA患者在3年(10.5个月; P = .048)时,无症状或无治疗毒性的QQTWiST显着改善了质量时间,每质量调整生命年增加的费用为2073.19欧元。胫骨EVR在CLI中可提供出色的结果。 CELA具有卓越的SCI,AFS,并且不受TER的限制,具有改进的Q-TWiST和成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号